NCT07175428View on ClinicalTrials.gov

Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

1,200

Participants

Timeline

Start Date

October 21, 2025

Primary Completion Date

April 26, 2027

Study Completion Date

April 26, 2027

Conditions

Atrial Fibrillation (AF)

Interventions

DRUG

REGN7508

Administered per the protocol

DRUG

REGN9933

Administered per the protocol

DRUG

Apixaban

Administered per the protocol

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY